--- title: "Nurix Therapeutics | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 9.043 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/292238137.md" datetime: "2026-07-09T20:11:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292238137.md) - [en](https://longbridge.com/en/news/292238137.md) - [zh-HK](https://longbridge.com/zh-HK/news/292238137.md) generator: "portal-rs" --- # Nurix Therapeutics | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 9.043 M Revenue: As of FY2026 Q2, the actual value is USD 9.043 M, missing the estimate of USD 15.29 M. EPS: As of FY2026 Q2, the actual value is USD -0.81, missing the estimate of USD -0.7264. EBIT: As of FY2026 Q2, the actual value is USD -89.81 M. #### Revenue Total revenue for Nurix Therapeutics, Inc. for the three months ended May 31, 2026, was $9.0 million, a decrease from $44.1 million for the same period in 2025, primarily attributed to $30 million of license revenue from two Sanofi license extensions in the prior year. Collaboration revenue for the quarter was $9.043 million in 2026, down from $14.056 million in 2025, while license revenue was $0 in 2026 compared to $30.000 million in 2025. For the six months ended May 31, 2026, total revenue was $15.295 million, down from $62.509 million in 2025. Nurix Therapeutics, Inc. earned a $2 million research milestone payment from Sanofi during the second fiscal quarter of 2026. #### Operating Expenses Research and development expenses for the three months ended May 31, 2026, increased to $87.7 million from $78.1 million for the same period in 2025, primarily due to increased clinical and contract manufacturing costs to accelerate patient enrollment in the Phase 2 trial of bexobrutideg and enable Phase 3 trial initiation. General and administrative expenses for the quarter rose to $15.6 million from $14.3 million in 2025, mainly due to higher legal costs related to collaboration and business development activities. Total operating expenses for the three months ended May 31, 2026, were $103.247 million, up from $92.378 million in 2025. For the six months ended May 31, 2026, research and development expenses were $171.789 million compared to $147.759 million in 2025, and general and administrative expenses were $30.205 million compared to $25.936 million in 2025. Total operating expenses for the six months were $201.994 million in 2026 versus $173.695 million in 2025. #### Net Loss Nurix Therapeutics, Inc. reported a net loss of -$89.5 million for the three months ended May 31, 2026, compared to a net loss of -$43.5 million for the same period in 2025. For the six months ended May 31, 2026, the net loss was -$176.709 million compared to -$99.815 million in 2025. #### Cash Position As of May 31, 2026, cash, cash equivalents, and marketable securities totaled $443.5 million, a decrease from $592.9 million as of November 30, 2025. Pro-forma cash, including the expected $700 million upfront payment from the Roche collaboration, was approximately $1.14 billion. #### Operational Highlights and Outlook Nurix Therapeutics, Inc. entered into a global collaboration agreement with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including an expected $700 million upfront payment in the third fiscal quarter of 2026 upon closing conditions. Development costs for bexobrutideg will be shared 40% by Nurix Therapeutics, Inc. and 60% by Roche, with U.S. profits and losses shared equally, and Nurix Therapeutics, Inc. eligible for tiered royalties on ex-U.S. sales. The company continues to advance its clinical pipeline, with enrollment ongoing in the DAYBreak CLL-201 pivotal Phase 2 trial and preparations for a global randomized Phase 3 confirmatory trial with the first patient dosing anticipated in mid-2026. ### Related Stocks - [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md) ## Related News & Research - [Edmond DE Rothschild Holding S.A. Invests $2.18 Million in Nurix Therapeutics, Inc. $NRIX](https://longbridge.com/en/news/296585941.md) - [Nurix Therapeutics Chief Legal Officer Christine Ring disposes of 16,589 common shares worth $382,324.26](https://longbridge.com/en/news/294742288.md) - [BioXcel Therapeutics amends Oaktree-led credit agreement, extends deadline for refinancing deal to Aug. 28](https://longbridge.com/en/news/296776940.md) - [Circle8 amends Form 8-K to correct typographical, drafting errors](https://longbridge.com/en/news/296348348.md) - [Rakovina Therapeutics adds Petra Hamerlik to board as Jeffrey Bacha retires](https://longbridge.com/en/news/296320749.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**